VRTX - Vertex Pharmaceuticals Incorporated

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
56.31B
Enterprise Value 3
52.96B
Trailing P/E
26.57
Forward P/E 1
32.83
PEG Ratio (5 yr expected) 1
1.55
Price/Sales (ttm)
15.56
Price/Book (mrq)
10.72
Enterprise Value/Revenue 3
14.63
Enterprise Value/EBITDA 6
58.51

Trading Information

Stock Price History

Beta (5Y Monthly) 1.49
52-Week Change 332.73%
S&P500 52-Week Change 324.46%
52 Week High 3225.66
52 Week Low 3151.80
50-Day Moving Average 3210.28
200-Day Moving Average 3184.46

Share Statistics

Avg Vol (3 month) 31.26M
Avg Vol (10 day) 31.12M
Shares Outstanding 5257.15M
Float 256.83M
% Held by Insiders 10.26%
% Held by Institutions 196.96%
Shares Short (Nov 29, 2019) 43.95M
Short Ratio (Nov 29, 2019) 42.79
Short % of Float (Nov 29, 2019) 41.72%
Short % of Shares Outstanding (Nov 29, 2019) 41.54%
Shares Short (prior month Oct 31, 2019) 44.28M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 21/2
Last Split Date 3Aug 24, 2000

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Sep 30, 2019

Profitability

Profit Margin 59.24%
Operating Margin (ttm)22.26%

Management Effectiveness

Return on Assets (ttm)8.30%
Return on Equity (ttm)51.75%

Income Statement

Revenue (ttm)3.62B
Revenue Per Share (ttm)14.14
Quarterly Revenue Growth (yoy)21.10%
Gross Profit (ttm)1.22B
EBITDA 905.3M
Net Income Avi to Common (ttm)2.14B
Diluted EPS (ttm)8.24
Quarterly Earnings Growth (yoy)-55.30%

Balance Sheet

Total Cash (mrq)4B
Total Cash Per Share (mrq)15.54
Total Debt (mrq)649.8M
Total Debt/Equity (mrq)12.37
Current Ratio (mrq)3.44
Book Value Per Share (mrq)20.42

Cash Flow Statement

Operating Cash Flow (ttm)1.44B
Levered Free Cash Flow (ttm)1.07B